 |
|
|
| |
Overall Safety Profile of Boceprevir Plus Peginterferon Alfa-2b/Ribavirin
|
| |
| |
Reported by Jules Levin EASL 2011 Berlin Germany March 31-Apr 2
M.P. Manns*1, F. Felizarta2, E. Schiff3, M. Burroughs4, V. Sniukiene4, N. Boparai4, C.A. Brass4, J.K. Albrecht4, J.M. Vierling5
1Medical School of Hannover, Hannover, Germany, 2Private practice, Bakersfield, CA, USA, 3University of Miami, Miami, FL, USA, 4Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA, 5Baylor College of Medicine, Houston, TX, USA ; *manns.michael@mh-hannover.de
References
1. AFSSAPS Institut National du Cancer. Epoetine beta. Available at http://www.afssaps.fr/
2. VHA Pharmacy Benefits Management Strategic Healthcare Group and Medical Advisory Panel. Recombinant Erythropoietin Criteria for Use for Hepatitis C Treatment-Related Anemia. Available at http://vaww.pbm.va.gov. VA 2011.
|
| |
|
|
|
|
|
